HER2 / neu in solid tumors: from a binary biomarker to a multilevel therapeutic target

作者
A. V. Shulga,Vadzim I. Talochka,С. А. Маскевич,Sokolova Za,А. А. Кныш,Igor R. Nabiev
出处
期刊:Rossijskij bioterapevtičeskij žurnal [Publishing House ABV Press]
卷期号:25 (3): 32-43
标识
DOI:10.17650/1726-9784-2026-25-3-32-43
摘要

Human epidermal growth factor receptor 2 (HER2, HER2/neu) is one of the most extensively studied and, at the same time, rapidly evolving molecular targets in modern oncology. Whereas the clinical significance of HER2 was initially associated almost exclusively with receptor overexpression and gene amplification in breast cancer, the spectrum of HER2-associated malignancies has now expanded substantially, and the very concept of HER2 positivity is undergoing a fundamental transformation. This review systematizes current knowledge of the biological role of HER2, the patterns of its overexpression, amplification, and activating mutations across solid tumors, as well as diagnostic approaches and opportunities for HER2-targeted therapy. Particular attention is given to breast, gastric and gastroesophageal junction, colorectal, and non-small-cell lung cancers, as well as tumors of the urinary bladder, biliary tract, salivary glands, and ovaries. HER2 protein overexpression, ERBB2 amplification, and activating mutations represent biologically and clinically distinct alterations and should not be indiscriminately grouped under the umbrella term “HER2-positive tumor”. The evolution of anti-HER2 therapy is traced from monoclonal antibodies and tyrosine kinase inhibitors to antibody – drug conjugates and bispecific antibodies. The emergence of highly effective antibody – drug conjugates, particularly trastuzumab deruxtecan, has extended the therapeutically relevant HER2 spectrum beyond classical overexpression, giving rise to the concepts of HER2-low and HER2-ultralow disease and facilitating the development of tumor-agnostic therapeutic approaches. The limitations of current methods for determining HER2 status are critically assessed, highlighting that direct extrapolation of diagnostic criteria established for breast cancer to other tumor types is not always methodologically justified. Emerging strategies to improve the sensitivity and objectivity of detecting low-level HER2 expression, including quantum dot-based fluorescent biosensors, are also considered. Collectively, current evidence supports a transition from binary HER2 assessment toward a multilevel model integrating receptor expression, ERBB2 amplification and mutational status, tumor type, and the therapeutic platform employed. This framework may enable more precise patient stratification and further expand the scope of personalized anticancer therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阿东发布了新的文献求助10
刚刚
刚刚
西陆发布了新的文献求助10
1秒前
秋风的应助被霍紫菡采纳,获得10
1秒前
NexusExplorer的应助被Cc采纳,获得10
2秒前
nixay621发布了新的文献求助10
2秒前
小航发布了新的文献求助10
3秒前
hsl完成签到 ,获得积分10
3秒前
三分之二发布了新的文献求助10
4秒前
陈攀完成签到,获得积分10
4秒前
苗条故事发布了新的文献求助10
4秒前
136586完成签到 ,获得积分10
4秒前
5秒前
wznx完成签到,获得积分10
6秒前
Jasper的应助被怀夕采纳,获得10
6秒前
6秒前
会发光的喷火龙完成签到,获得积分10
8秒前
L1完成签到,获得积分10
8秒前
9秒前
神奇的大蛇丸完成签到,获得积分10
9秒前
桐桐的应助被快乐是无敌采纳,获得10
9秒前
踏实尔阳完成签到,获得积分10
9秒前
叶子发布了新的文献求助10
9秒前
灼灼朗朗完成签到,获得积分10
10秒前
王帅松完成签到,获得积分10
10秒前
10秒前
10秒前
11秒前
HZH完成签到,获得积分10
11秒前
壮观白风完成签到 ,获得积分10
11秒前
11秒前
香蕉觅云的应助被Ariel采纳,获得10
11秒前
12秒前
NexusExplorer的应助被Layman采纳,获得10
12秒前
酱紫完成签到 ,获得积分10
13秒前
iitj完成签到,获得积分10
13秒前
啄春泥完成签到,获得积分10
14秒前
dudu发布了新的文献求助10
14秒前
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177767
求助须知:如何正确求助?哪些是违规求助? 9568590
关于积分的说明 21799821
捐赠科研通 7772374
什么是DOI,文献DOI怎么找? 3432476
关于科研通互助平台的介绍 2556695
邀请新用户注册赠送积分活动 2478034